<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556162</url>
  </required_header>
  <id_info>
    <org_study_id>BC-05673</org_study_id>
    <nct_id>NCT04556162</nct_id>
  </id_info>
  <brief_title>Evaluation of Salt Status in Patients With Cystic Fibrosis</brief_title>
  <official_title>Evaluation of Salt Status in Patients With Cystic Fibrosis and the Influence on Nutritional Status and Pulmonary Function. Looking for the Best Surrogate Urinary Markers for Fractional Sodium or Chloride Excretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The results of the annual check-up will be collected to evaluate the best urinary marker for&#xD;
      fractional sodium excretion and salt status will be correlated to clinical outcome measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cystic fibrosis need extra salt as they have increased losses through sweat.&#xD;
      Current advices are to follow and supplement if needed, however the way to follow salt&#xD;
      depletion is unclear.&#xD;
&#xD;
      The best way is to calculate fractional salt excretion. This needs a simultaneous blood and&#xD;
      urine sample for electrolytes and creatinin. Urinary surrogate markers have been validated on&#xD;
      only 10 patients.&#xD;
&#xD;
      At the annual check-up patients with cystic fibrosis receive these measurements. The&#xD;
      investigators will collect the measurements and calculate fractional excretion and the&#xD;
      possible surrogate markers on urine. Further this will be correlated to nutritional and&#xD;
      pulmonary status and patient subgroups at risk will be identified.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fractional sodium excretion (percent)</measure>
    <time_frame>1 year</time_frame>
    <description>= (serum creatinin X urinary Sodium)/(plasma sodiumX urinary creatinin)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary sodium/urinary creatinin (mmol/mmol)</measure>
    <time_frame>1 year</time_frame>
    <description>calculated based on urinary results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional Chloride excretion (percent)</measure>
    <time_frame>1 year</time_frame>
    <description>= (serum creatinin X urinary Chloride)/(plasma Chloride X urinary creatinin)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional Potassium excretion (%)</measure>
    <time_frame>1 year</time_frame>
    <description>= (serum creatinin X urinary Potassium)/(plasma PotassiumX urinary creatinin)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ratio urinary sodium/urinary potassium</measure>
    <time_frame>1 year</time_frame>
    <description>= calculation of ration urinary sodium/potassium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>1 year</time_frame>
    <description>= Weight/Height X Height expressed as SD of the local population based on Flemish growth charts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 second</measure>
    <time_frame>1 year</time_frame>
    <description>measured with lungfunction testing expressed as % of normal for height</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Salt; Deficit (or Low)</condition>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>fractional sodium excretion</intervention_name>
    <description>fractional sodium excretion will be compared to urinary sodium/creatinin, sodium/potassium ratio's and sodium concentration.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>risk subgroups</intervention_name>
    <description>subgroup analysis will be performed to identify the patient groups at risk for sodium depletion</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All cystic fibrosis patients for whom a complete analysis of both blood and urine is&#xD;
        available at the time of their annual check-up&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all cystic fibrosis patients followed at the Gent University Cystic fibrosis centre&#xD;
&#xD;
          -  Providing a paired urine and blood sample at the time of their annual check-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  transplantation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Van Biervliet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gent University hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Van Biervliet, MD, PhD</last_name>
    <phone>93325514</phone>
    <phone_ext>+32</phone_ext>
    <email>stephanie.vanbiervliet@ugent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dimitri Declercq, RDN</last_name>
    <phone>93326504</phone>
    <phone_ext>+32</phone_ext>
    <email>dimitri.declercq@uzgent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Van Biervliet, MD PhD</last_name>
      <phone>93325514</phone>
      <phone_ext>+32</phone_ext>
      <email>stephanie.vanbiervliet@ugent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

